Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 9/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12184997 | 0.83 | ALK (0.52) | ALKGPBAR1IGF1R | |
| SCHEMBL15022109 | 0.78 | TRPV1 (0.44) | GPBAR1TRPV1 | |
| SCHEMBL2635130 | 0.69 | TRPV1 (0.36) | ALKTRPV1 | |
| SCHEMBL29438234 | 0.68 | ALDH1A1 (0.54) | GPBAR1 | |
| SCHEMBL2635948 | 0.68 | ALDH1A1 (0.54) | GPBAR1 | |
| SCHEMBL12185358 | 0.68 | ALDH1A1 (0.54) | GPBAR1 | |
| SCHEMBL12185389 | 0.68 | ALK (0.75) | ALKGPBAR1IGF1R | |
| SCHEMBL2635263 | 0.68 | ALK (0.75) | ALKGPBAR1IGF1R | |
| SCHEMBL12184891 | 0.68 | ALK (0.75) | ALKGPBAR1IGF1R | |
| SCHEMBL6869759 | 0.67 | MAPT (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2600874-B1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8716281-B2 | Pyrimidine compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2600874-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-06-12 | — | — | EP | disclosed |
| WO-2011143033-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158019-A1 | PYRIMIDINE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | DCK, DTYMK, TYMS | ALK 53/4885GRIN2B 3259/4885GPBAR1 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.